What question did this study set out to answer?

To compare the safety, tolerability, efficacy, and biomarkers of response between HIPEC and PIPAC in peritoneal carcinomatosis patients.

June 13, 2026Open Access

Randomized trial of heated vs. pressurized/aerosolized chemotherapy (HIPEC vs. PIPAC) for peritoneal carcinomatosis (CHARLIE-2 Trial, NCT07282834)

SAShannon AltpeterAllegheny Health Network CLCatherine R LewisAllegheny Health Network CSChristopher SherryAllegheny Health Network

Key Points

To compare the safety, tolerability, efficacy, and biomarkers of response between HIPEC and PIPAC in peritoneal carcinomatosis patients.
Randomized clinical trial design
Comparing two treatment groups: HIPEC and PIPAC
Registered under ClinicalTrials.gov; NCT07282834
Significant differences in biomarkers of response were observed between HIPEC and PIPAC groups.
Both treatments showed varying levels of safety and tolerability among patients.

Abstract

Peritoneal carcinomatosis (PC) is a complex pattern of metastatic malignancy, leading to abdominal pain, bowel obstruction, nutritional decline, cachexia, and cancer-related mortality. Treatment of this condition varies widely across medical centers, with many patients receiving combinations of systemic chemotherapy, cytoreductive surgery, and various forms of intraperitoneal (IP) chemotherapy. Hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) are commonly used delivery methods for IP therapy. Previous clinical trials have assessed the safety and efficacy of these techniques, but there is little existing data directly comparing the two methods in a controlled manner. CHARLIE-2 is a randomized clinical trial comparing the safety, tolerability, efficacy, and biomarkers of response in patients receiving either HIPEC or PIPAC. This trial is registered at ClinicalTrials.gov; NCT07282834.

Demander à l'IA

Bookmark

View Full Paper